AP2014007571A0 - Anti IL-36R antibodies - Google Patents

Anti IL-36R antibodies

Info

Publication number
AP2014007571A0
AP2014007571A0 AP2014007571A AP2014007571A AP2014007571A0 AP 2014007571 A0 AP2014007571 A0 AP 2014007571A0 AP 2014007571 A AP2014007571 A AP 2014007571A AP 2014007571 A AP2014007571 A AP 2014007571A AP 2014007571 A0 AP2014007571 A0 AP 2014007571A0
Authority
AP
ARIPO
Prior art keywords
antibodies
Prior art date
Application number
AP2014007571A
Other languages
English (en)
Inventor
Su-Ellen Brown
Keith Canada
Lukasz Chlewicki
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47215803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2014007571(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AP2014007571A0 publication Critical patent/AP2014007571A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2014007571A 2011-11-16 2012-11-14 Anti IL-36R antibodies AP2014007571A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161560554P 2011-11-16 2011-11-16
US201261644111P 2012-05-08 2012-05-08
US201261713713P 2012-10-15 2012-10-15
PCT/US2012/064933 WO2013074569A1 (fr) 2011-11-16 2012-11-14 Anticorps anti-il-36r

Publications (1)

Publication Number Publication Date
AP2014007571A0 true AP2014007571A0 (en) 2014-04-30

Family

ID=47215803

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007571A AP2014007571A0 (en) 2011-11-16 2012-11-14 Anti IL-36R antibodies

Country Status (41)

Country Link
US (4) US9023995B2 (fr)
EP (2) EP2780373B1 (fr)
JP (3) JP6289375B2 (fr)
KR (3) KR20200110476A (fr)
CN (5) CN112812183B (fr)
AP (1) AP2014007571A0 (fr)
AR (1) AR089178A1 (fr)
AU (1) AU2012339734B2 (fr)
BR (1) BR112014011594B1 (fr)
CA (1) CA2852994C (fr)
CL (1) CL2014001123A1 (fr)
CO (1) CO7020871A2 (fr)
CY (2) CY1122278T1 (fr)
DK (2) DK2780373T3 (fr)
EA (1) EA031948B1 (fr)
EC (1) ECSP14004976A (fr)
ES (2) ES2755732T3 (fr)
FI (2) FI3536710T3 (fr)
FR (1) FR23C1023I2 (fr)
GE (1) GEP20186816B (fr)
HR (2) HRP20251675T1 (fr)
HU (2) HUE047437T2 (fr)
IL (2) IL232100B (fr)
LT (3) LT2780373T (fr)
LU (1) LUC00308I2 (fr)
MX (1) MX347164B (fr)
MY (1) MY195289A (fr)
NL (1) NL301233I2 (fr)
NO (2) NO2023024I1 (fr)
PE (1) PE20142041A1 (fr)
PH (1) PH12014501108A1 (fr)
PL (2) PL2780373T3 (fr)
PT (2) PT2780373T (fr)
RS (2) RS59248B1 (fr)
SG (1) SG11201402283PA (fr)
SI (2) SI2780373T1 (fr)
TW (1) TWI573804B (fr)
UA (1) UA115540C2 (fr)
UY (1) UY34456A (fr)
WO (1) WO2013074569A1 (fr)
ZA (1) ZA201402491B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252076B1 (fr) 2011-01-14 2019-09-04 The Regents Of The University Of California Utilisation diagnostique d' anticorps thérapeutiques contre la protéine ror-1
SI2780373T1 (sl) 2011-11-16 2019-12-31 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
EA201691765A1 (ru) * 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
RU2582569C2 (ru) * 2014-07-24 2016-04-27 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека, днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека с с-концевым полигистидиновым тагом, плазмидный экспрессионный вектор (варианты), штамм бактерий escherichia coli bl21 star[de3] (рет-il36raf), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 и штамм бактерий escherichia coli bl21 star[de3] (pet-il36raf-his), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 с с-концевым полигистидиновым тагом
PL3277321T3 (pl) 2015-04-01 2024-11-18 Anaptysbio, Inc. Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
US10526410B2 (en) * 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)
EP3307772B1 (fr) * 2015-06-12 2020-09-09 Ludwig Institute For Cancer Research Limited Anticorps spécifiques de tgf-bêta 3 et procédés et utilisations associés
JP6654773B2 (ja) * 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
MA50677A (fr) 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
AU2018205401B2 (en) 2017-01-09 2025-01-02 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
EP3601350A1 (fr) * 2017-03-27 2020-02-05 Boehringer Ingelheim International GmbH Polythérapie à base d'anticorps anti il-36r
ES3067325T3 (en) * 2018-01-08 2026-05-21 Chemocentryx Inc Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
AU2019236105B2 (en) * 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
WO2019177883A2 (fr) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Utilisation d'anticorps anti-il-36 r pour le traitement d'une maladie intestinale inflammatoire
KR102895164B1 (ko) * 2018-07-16 2025-12-04 리제너론 파마슈티칼스 인코포레이티드 항-il36r 항체
CA3098040A1 (fr) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Modeles animaux non humains de maladie ditra et leurs utilisations
JP2022532812A (ja) 2018-08-16 2022-07-20 カンタージア アクチエボラーグ 抗ｉｌ１ｒａｐ抗体組成物
US20210380675A1 (en) * 2018-09-28 2021-12-09 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
MX2021007589A (es) * 2018-12-21 2021-12-10 23Andme Inc Anticuerpos anti il-36 y procedimientos de uso de estos.
KR20210119407A (ko) * 2018-12-27 2021-10-05 베링거 인겔하임 인터내셔날 게엠베하 수장 족저 농포증 치료용 항-il-36r 항체
US11730812B2 (en) * 2019-03-08 2023-08-22 Boehringer Ingelheim International Gmbh Anti-IL-36R antibody formulations
JP7811772B2 (ja) * 2019-12-05 2026-02-06 学校法人東京薬科大学 筋組織の減少を抑制するための組成物
AR120913A1 (es) * 2019-12-27 2022-03-30 Teijin Pharma Ltd Anticuerpo que inhibe específicamente la señalización de il-36r
TW202208433A (zh) 2020-05-19 2022-03-01 德商百靈佳殷格翰國際股份有限公司 用於治療異位性皮膚炎之抗ｉｌ－３６ｒ抗體
MX2023000763A (es) 2020-07-17 2023-02-13 Boehringer Ingelheim Int Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
WO2022026832A1 (fr) 2020-07-30 2022-02-03 Anaptysbio, Inc. Thérapie contre l'ichtyose à anti-récepteur de l'interleukine 36 (il-36r)
WO2022026829A1 (fr) 2020-07-30 2022-02-03 Anaptysbio, Inc. Thérapie anti-récepteur de l'interleukine 36 (il-36r) pour traiter la toxicité cutanée
AU2021353854A1 (en) 2020-09-30 2023-05-04 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for treatment of chronic inflammatory pain
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
EP4289863A4 (fr) * 2020-12-17 2025-04-09 Shanghai Huaota Biopharmaceutical Co., Ltd. Anticorps bispécifique ciblant il-17a et il-36r et son application
WO2022150644A1 (fr) 2021-01-08 2022-07-14 Anaptysbio, Inc. Thérapie contre l'acné par récepteur de l'interleukine 36 (il-36r)
WO2022150642A1 (fr) 2021-01-08 2022-07-14 Anaptysbio, Inc. Thérapie anti-récepteur de l'interleukine 36 (il-36r) contre la maladie de verneuil
CN114907477A (zh) * 2021-02-08 2022-08-16 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
BR112023014103A2 (pt) 2021-03-04 2023-10-10 Boehringer Ingelheim Int Métodos para o tratamento de gpp
EP4305207A2 (fr) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarqueurs associés au traitement par anticorps anti-il-36 r dans le psoriasis pustuleux généralisé
MX2023012903A (es) * 2021-05-03 2023-11-08 Boehringer Ingelheim Int Metodo para producir spesolimab.
WO2022262828A1 (fr) * 2021-06-18 2022-12-22 正大天晴药业集团股份有限公司 Anticorps anti-il-36r et son utilisation
WO2023285362A1 (fr) 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'inhibiteurs d'il-36 permettant le traitement du syndrome de netherton
WO2023019232A1 (fr) 2021-08-13 2023-02-16 Boehringer Ingelheim International Gmbh Anticorps anti-il-36r pour le traitement d'un état fibrotique
WO2023052222A2 (fr) 2021-09-28 2023-04-06 Boehringer Ingelheim International Gmbh Système et méthode d'évaluation de la gravité de dermatoses neutrophiles avec manifestation cutanée visible
IL312360A (en) * 2021-10-28 2024-06-01 Abbvie Inc Anti-amyloid beta antibodies and methods of using them
TW202323293A (zh) * 2021-10-29 2023-06-16 新加坡商創響私人有限公司 新型抗ｉｌ－３６ｒ抗體
CN115724975B (zh) * 2022-10-20 2026-06-09 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用
CN116574189A (zh) 2023-01-30 2023-08-11 北京智仁美博生物科技有限公司 针对人il-36r和/或人il-1r3的多种抗体及其用途
WO2024175031A1 (fr) 2023-02-21 2024-08-29 江苏恒瑞医药股份有限公司 Protéine de liaison à il-36r et son utilisation médicinale
AU2024233450A1 (en) 2023-03-09 2025-08-14 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for the treatment of hidradentitis suppurativa (hs)
WO2024251927A2 (fr) 2023-06-09 2024-12-12 Boehringer Ingelheim International Gmbh Procédés de traitement et de prévention de gpp

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (fr) 1979-10-18 1981-04-30 Univ Illinois Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
WO1990003430A1 (fr) 1988-09-23 1990-04-05 Cetus Corporation Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
CA2140933A1 (fr) 1992-08-21 1994-02-22 Paula M. Jardieu Methode de traitement pour les atteintes dues a la molecule lfa-1
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
EP1798286B1 (fr) 1997-08-01 2011-09-07 Schering Corporation Protéines de membrane cellulaire mammalienne et réactifs associes
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
PT2857516T (pt) * 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
EP1627927A3 (fr) * 2001-03-01 2006-06-07 Epigenomics AG Méthode, système et programme informatique permettant de déterminer l'effet biologique et/ou l'activité de médicaments, de substances chimiques et/ou compositions pharmaceutiques en fonction de leur effet sur l'état de méthylation de l'ADN.
CA2499891A1 (fr) * 2002-10-03 2004-04-15 Large Scale Biology Corporation Ingenierie des proteines multimeriques
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20140053410A (ko) * 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US8034771B2 (en) 2006-09-08 2011-10-11 Amgen Inc. IL-1F6 polypeptides
JP2010526066A (ja) 2007-04-23 2010-07-29 シェーリング コーポレイション 抗ｍｄｌ−１抗体
ES2540854T3 (es) 2007-06-29 2015-07-14 Merck Sharp & Dohme Corp. Usos de antagonistas MDL-1
KR20110048536A (ko) * 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도
SI2780373T1 (sl) 2011-11-16 2019-12-31 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
US10526410B2 (en) 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)

Also Published As

Publication number Publication date
EP2780373B1 (fr) 2019-08-21
NL301233I1 (fr) 2023-06-07
CY2023014I2 (el) 2023-11-15
BR112014011594B1 (pt) 2021-11-09
NO2025001I1 (no) 2025-01-03
PT3536710T (pt) 2026-01-20
JP6719490B2 (ja) 2020-07-08
IL272035A (en) 2020-02-27
ECSP14004976A (es) 2015-11-30
AU2012339734B2 (en) 2017-02-16
CN112812183B (zh) 2024-06-11
CA2852994A1 (fr) 2013-05-23
JP6289375B2 (ja) 2018-03-07
EP3536710B1 (fr) 2025-10-29
LTPA2023518I1 (fr) 2023-06-12
US20200231684A1 (en) 2020-07-23
KR102038310B1 (ko) 2019-11-01
SI2780373T1 (sl) 2019-12-31
ES2755732T3 (es) 2020-04-23
PL2780373T3 (pl) 2020-03-31
PT2780373T (pt) 2019-11-27
BR112014011594A2 (pt) 2017-07-04
FIC20230020I1 (fi) 2023-06-01
US9023995B2 (en) 2015-05-05
CN118515766A (zh) 2024-08-20
KR20190122877A (ko) 2019-10-30
CY2023014I1 (el) 2023-11-15
FR23C1023I1 (fr) 2023-07-21
EP3536710A1 (fr) 2019-09-11
JP2020156506A (ja) 2020-10-01
FI3536710T3 (fi) 2026-01-14
LTC2780373I2 (fr) 2024-11-11
CN118496365A (zh) 2024-08-16
HUE047437T2 (hu) 2020-04-28
IL232100A0 (en) 2014-05-28
LT3536710T (lt) 2026-01-26
AU2012339734A1 (en) 2014-04-24
IL232100B (en) 2020-04-30
NO2023024I1 (no) 2023-05-30
DK3536710T3 (da) 2026-01-19
MX347164B (es) 2017-04-18
US20170298135A9 (en) 2017-10-19
HRP20191835T1 (hr) 2019-12-27
JP2018093885A (ja) 2018-06-21
RS67639B1 (sr) 2026-02-27
KR20200110476A (ko) 2020-09-23
DK2780373T3 (da) 2019-11-04
RS59248B1 (sr) 2019-10-31
PH12014501108B1 (en) 2014-08-04
LUC00308I2 (fr) 2025-09-22
LT2780373T (lt) 2019-09-25
KR20140101738A (ko) 2014-08-20
CN104080808B (zh) 2016-11-16
CL2014001123A1 (es) 2015-01-23
US20130236471A1 (en) 2013-09-12
PE20142041A1 (es) 2014-12-18
CA2852994C (fr) 2023-02-14
JP2015500633A (ja) 2015-01-08
SG11201402283PA (en) 2014-06-27
ZA201402491B (en) 2021-09-29
UA115540C2 (uk) 2017-11-27
PL3536710T3 (pl) 2026-04-13
CN107007833A (zh) 2017-08-04
MX2014005759A (es) 2014-09-08
AR089178A1 (es) 2014-08-06
CY1122278T1 (el) 2020-11-25
GEP20186816B (en) 2018-02-12
CO7020871A2 (es) 2014-08-11
PH12014501108A1 (en) 2014-08-04
NL301233I2 (nl) 2023-09-13
HUS2300021I1 (hu) 2023-07-28
MY195289A (en) 2023-01-12
US10550189B2 (en) 2020-02-04
US20240409648A1 (en) 2024-12-12
UY34456A (es) 2013-05-31
WO2013074569A1 (fr) 2013-05-23
SI3536710T1 (sl) 2026-04-30
US20150203584A1 (en) 2015-07-23
NZ623425A (en) 2015-12-24
TWI573804B (zh) 2017-03-11
CN104080808A (zh) 2014-10-01
EA031948B1 (ru) 2019-03-29
HRP20251675T1 (hr) 2026-02-13
EA201400579A1 (ru) 2014-10-30
KR102159109B1 (ko) 2020-09-23
TW201333037A (zh) 2013-08-16
ES3058874T3 (en) 2026-03-13
CN107007833B (zh) 2020-12-11
CN112812183A (zh) 2021-05-18
FR23C1023I2 (fr) 2024-03-29
EP2780373A1 (fr) 2014-09-24

Similar Documents

Publication Publication Date Title
IL272035A (en) Anti IL–36R antibodies
ES3065861T3 (en) Interleukin-31 monoclonal antibody
IL259826A (en) Anti-alphabetatisiar antibody
TWI561531B (en) Anti b7-h3 antibody
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
ZA201305323B (en) Cea antibodies
SG10201609665PA (en) FcɣRIIb-SPECIFIC Fc ANTIBODY
TWI563004B (en) Anti-hxcr1 antibody
EP2714074A4 (fr) Anticorps anti-emr1
GB201116342D0 (en) Antigen combinations